Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | SC |
Menveo SQ instead of IM; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of intramuscular formulation administered by other route in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received Menveo (subcutaneous). On an unknown date, an unknown time after receiving Menveo, the patient experienced intramuscular formulation administered by other route (Verbatim: Menveo SQ instead of IM). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK receipt date 20-FEB-2026 The pharmacist enquired whether vaccine should be readministered. The batch number was not provided and a request for this information has been made.